Preventive medicine · 2026
Associations of delta-9-tetrahydrocannabinol quantity and Cannabis use frequency with Cannabis use disorder among adults who use Cannabis in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Borodovsky Jacob T, Wall Melanie, Struble Cara A, Liu Jun, Budney Alan J, Hasin Deborah S
Аннотация
OBJECTIVE: We examined how milligrams of delta-9-tetrahydrocannabinol (mgTHC) per using day and cannabis use frequency relate to cannabis use disorder (CUD).
METHODS: From Aug 2024-Jan 2025, N = 3303 past-month cannabis users in the United States completed the Cannabis Exposure Index online survey. We used logistic and linear regression to examine three CUD outcomes: (1) diagnosis, (2) individual criterion endorsement, and (3) total criteria count. Model predictors included mgTHC per using day, cannabis use frequency, and sociodemographics.
RESULTS: Higher mgTHC predicted greater odds of CUD (OR = 1.28, 95% CI: 1.20, 1.37) and greater criteria count (β = 0.84, 95% CI: 0.61, 1.07). Participants who used cannabis on 1-10 days had lower CUD odds than daily users (OR = 0.28, 95% CI: 0.20, 0.40). mgTHC was a stronger predictor of CUD among lower-frequency than higher-frequency users (interaction p = 0.030). Higher mgTHC was most strongly associated with the time spent, tolerance, and hazardous use criteria.
CONCLUSIONS: Both mgTHC and frequency were associated with CUD. Cannabis exposure may be characterized more accurately by considering both how often cannabis is used and how much THC is consumed on use days.
METHODS: From Aug 2024-Jan 2025, N = 3303 past-month cannabis users in the United States completed the Cannabis Exposure Index online survey. We used logistic and linear regression to examine three CUD outcomes: (1) diagnosis, (2) individual criterion endorsement, and (3) total criteria count. Model predictors included mgTHC per using day, cannabis use frequency, and sociodemographics.
RESULTS: Higher mgTHC predicted greater odds of CUD (OR = 1.28, 95% CI: 1.20, 1.37) and greater criteria count (β = 0.84, 95% CI: 0.61, 1.07). Participants who used cannabis on 1-10 days had lower CUD odds than daily users (OR = 0.28, 95% CI: 0.20, 0.40). mgTHC was a stronger predictor of CUD among lower-frequency than higher-frequency users (interaction p = 0.030). Higher mgTHC was most strongly associated with the time spent, tolerance, and hazardous use criteria.
CONCLUSIONS: Both mgTHC and frequency were associated with CUD. Cannabis exposure may be characterized more accurately by considering both how often cannabis is used and how much THC is consumed on use days.